1 |
NCT01796015 |
Completed |
Intracranial Hypertension and Optic Nerve Sheath Diameter |
- Cerebral Stroke
- Cerebral Venous Thrombosis
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Primary (sensitivity and specificity of echographic measurement of ONSD)
- Secondary outcome (1. To draw learning curves before the study begins to find out the number of ultrasound measurement needed)
|
230 |
All |
2 Months to 16 Years (Child) |
NCT01796015 |
2010.598 |
DENO |
April 2011 |
February 2017 |
February 2017 |
February 21, 2013 |
March 3, 2017 |
|
- Pediatric Critical Care Unit, Hôpital Femme Mère Enfant ,Hospices Civils de Lyon
Bron, Rhône Alpes, France - Pediatric Critical Care Unit, CHU La Tronche
Grenoble, France
|
2 |
NCT01675310 |
Completed |
Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women |
- Pregestational Obesity (BMI > 27kg/m2)
- History of Polycystic Ovary Syndrome
|
- Drug: medical nutrition therapy + metformin
- Behavioral: Medical nutrition therapy
|
Interventional |
Phase 4 |
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
- National Council of Science and Technology, Mexico
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Gestational diabetes mellitus
- insulin resistance
|
90 |
Female |
18 Years to 50 Years (Adult) |
NCT01675310 |
Conacyt 151819 INPer (Mexico) |
|
January 2012 |
December 2014 |
March 2015 |
August 29, 2012 |
March 25, 2015 |
|
- National Institute of Perinatology
Mexico, Mexico
|
3 |
NCT01538147 |
Completed |
Restless Leg Syndrome and Severe Preeclampsia |
- Restless Leg Syndrome
- Severe Preeclampsia
|
|
Observational |
|
- Saint Thomas Hospital, Panama
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
310 |
Female |
Child, Adult, Senior |
NCT01538147 |
MHST2012-02 |
|
August 1, 2017 |
November 30, 2017 |
December 15, 2017 |
February 23, 2012 |
January 4, 2018 |
|
- Saint Thomas Maternity Hospital
Panama, Panama
|
4 |
NCT02332304 |
Completed |
Amniotic Fluid Optical Density Determination as a Test for Assessment of Fetal Lung Maturity. |
- Respiratory Distress Syndrome, Newborn
|
|
Interventional |
Phase 3 |
- Saint Thomas Hospital, Panama
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Respiratory Distress Syndrome, Newborn
|
200 |
Female |
Child, Adult, Senior |
NCT02332304 |
MHST2014-02 |
|
May 2014 |
November 2014 |
December 2014 |
January 6, 2015 |
January 6, 2015 |
|
- Saint Thomas Maternity Hospital
Panama, Panama
|
5 |
NCT01538134 |
Unknown † |
Antiphospholipid Antibodies and Fetal Growth Restriction |
- Fetal Growth Restriction
- Antiphospholipid Syndrome
|
|
Observational |
|
- Saint Thomas Hospital, Panama
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Lupus anticoagulant
- Anticardiolipin antibodies
- B2 Glycoprotein I
|
90 |
Female |
Child, Adult, Senior |
NCT01538134 |
MHST2012-01B |
|
June 2015 |
February 2016 |
March 2016 |
February 23, 2012 |
January 5, 2015 |
|
- Saint Thomas Maternity Hospital
Panama, Panama
|
6 |
NCT03090997 |
Recruiting |
Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women |
- Postmenopausal
- Insulin Resistance
|
- Dietary Supplement: vitamin C (500 mg / day) + placebo
- Dietary Supplement: resveratrol (500 mg / day) + placebo
- Dietary Supplement: vitamin C (500 mg / day) and resveratrol (500 mg / day)
|
Interventional |
Not Applicable |
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Insulin resistance
- Superoxide dismutase activity
- Catalase activity
- (and 4 more...)
|
270 |
Female |
50 Years to 60 Years (Adult) |
NCT03090997 |
3210-10209-01-574-17 |
|
February 15, 2018 |
November 30, 2019 |
August 20, 2020 |
March 27, 2017 |
March 1, 2018 |
|
- Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Mexico City, Mexico
|
7 |
NCT01538121 |
Unknown † |
Antiphospholipid Antibodies and Early Severe Preeclampsia. |
- Severe Preeclampsia
- Antiphospholipid Syndrome
|
|
Observational |
|
- Saint Thomas Hospital, Panama
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Lupus anticoagulant
- Anticardiolipin antibodies
- B2 Glycoprotein I
|
310 |
Female |
Child, Adult, Senior |
NCT01538121 |
MHST2012-01A |
|
June 2015 |
July 2016 |
August 2016 |
February 23, 2012 |
January 5, 2015 |
|
- Saint Thomas Maternity Hospital
Panama, Panama
|
8 |
NCT00890383 |
Completed |
Colloids in Severe Trauma |
- Abdominal Hypertension
- Abdominal Compartment Syndrome
- Severe Trauma
|
- Drug: tetrastarch (Voluven)
|
Interventional |
Phase 4 |
- University of the Philippines
- Fresenius Kabi
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Intraabdominal hypertension
- abdominal compartment syndrome
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT00890383 |
GCS Sur 2007-030 |
CIST |
May 2009 |
November 2009 |
November 2009 |
April 29, 2009 |
November 25, 2009 |
|
- Jose Reyes Memorial Medical Center
Manila, Metro Manila, Philippines - East Avenue Medical Center
Quezon City, NCR, Philippines
|
9 |
NCT00737724 |
Terminated |
Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment |
|
- Drug: Simultaneous ARV and antiMTB
- Drug: Deferred RV and antiMTB treatment
|
Interventional |
Not Applicable |
- Instituto Nacional de Enfermedades Respiratorias
- Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to remission of signs and symptoms of active tuberculosis as well as general symptoms.
- Time to negative measurement of mycobacterial load in body fluids or affected tissues
- CD4+ cell count increase
- (and 2 more...)
|
63 |
All |
18 Years to 60 Years (Adult) |
NCT00737724 |
C43-06 |
|
March 2008 |
February 2011 |
February 2011 |
August 20, 2008 |
March 26, 2015 |
|
- Centro de Investigaciones en Enfermedades Infecciosas
Mexico city, DF, Mexico - Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
|
10 |
NCT00469846 |
Terminated |
L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia |
|
- Procedure: L-arginine supplementation in a medical food
- Procedure: Vitamin C and E supplementation in a medical food
|
Interventional |
Phase 2 |
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
- University of Pennsylvania
- Bill and Melinda Gates Foundation
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Development of preeclampsia
- Development of eclampsia
- Occurrence of HELP syndrome
- (and 2 more...)
|
585 |
Female |
19 Years to 32 Years (Adult) |
NCT00469846 |
212250-02071 |
L-Arg |
January 2001 |
|
November 2006 |
May 7, 2007 |
May 8, 2007 |
|
- Univesity of Pennsylvania
Philadelphia, Pennsylvania, United States - Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Mexico City, D.f., Mexico
|
11 |
NCT03226821 |
Recruiting |
Body Composition and Adipose Tissue in HIV |
- HIV Lipodystrophy Syndrome
- Growth Hormone Deficiency
- Body Composition
|
|
Interventional |
Phase 4 |
- Columbia University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Hepatic Lipid Content
- Change in Visceral Adipose Tissue (VAT) mass
- Change in Relative gene expression of CD68 gene
- (and 2 more...)
|
24 |
All |
18 Years to 68 Years (Adult, Senior) |
NCT03226821 |
AAAR2634 R01DK110771 |
|
February 7, 2018 |
April 30, 2021 |
April 30, 2021 |
July 24, 2017 |
April 11, 2018 |
|
- Neuroendocrine Unit and Pituitary Center, Columbia University
New York, New York, United States
|
12 |
NCT02521753 |
Recruiting |
Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients |
- Polycystic Ovary Syndrome
- Obesity
|
- Drug: Metformin
- Dietary Supplement: Magnesium
- Dietary Supplement: PUFA
|
Interventional |
Not Applicable |
- Coordinación de Investigación en Salud, Mexico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Metabolic profile
- Hormonal profile
|
123 |
Female |
18 Years to 38 Years (Adult) |
NCT02521753 |
R-2014-785-056 |
OMgObPCOS |
August 2015 |
February 2018 |
December 2018 |
August 13, 2015 |
February 1, 2017 |
|
- Hospital de Gineco Obstetricia Centro Médico "La Raza"
Mexico City, D.f., Mexico
|
13 |
NCT03100942 |
Recruiting |
Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome |
|
- Drug: Filgotinib
- Drug: GS-9876
- Drug: Tirabrutinib
- (and 3 more...)
|
Interventional |
Phase 2 |
- Gilead Sciences
- Galapagos NV
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline
- Change from Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12
- Change from Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12
- (and 2 more...)
|
140 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03100942 |
GS-US-445-4189 2016-003558-34 |
|
May 1, 2017 |
March 2019 |
December 2019 |
April 4, 2017 |
April 26, 2018 |
|
- AARR Arizona Arthritis & Rheumatology Research
Mesa, Arizona, United States - AARR Arizona Arthritis & Rheumatology Research
Phoenix, Arizona, United States - Medvin Clinical Research
Covina, California, United States - (and 59 more...)
|
14 |
NCT02631538 |
Recruiting |
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome |
|
- Drug: Belimumab
- Drug: Rituximab
- Drug: Placebo belimumab
- Drug: Placebo rituximab
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of participants with SAEs
- Number of participants with AESIs
- The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score over time
- (and 3 more...)
|
79 |
All |
18 Years and older (Adult, Senior) |
NCT02631538 |
201842 |
|
February 17, 2016 |
June 28, 2019 |
June 26, 2020 |
December 16, 2015 |
April 20, 2018 |
|
- GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina - GSK Investigational Site
Buenos Aires, Argentina - GSK Investigational Site
Ciudad Autonoma Buenos Aires, Argentina - (and 42 more...)
|
15 |
NCT00831441 |
Terminated Has Results |
Phase III Acute Coronary Syndrome |
|
- Drug: Apixaban
- Drug: Placebo
|
Interventional |
Phase 3 |
- Bristol-Myers Squibb
- Pfizer
- Duke Clinical Research Institute
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants
- Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants
- Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants
- (and 9 more...)
|
7484 |
All |
18 Years and older (Adult, Senior) |
NCT00831441 |
CV185-068 EUDRACT# 2008-008298-77 |
APPRAISE-2 |
March 2009 |
March 2011 |
March 2011 |
January 29, 2009 |
January 27, 2016 |
January 27, 2016 |
- Uab Medical Center
Birmingham, Alabama, United States - University Of Alabama At Birmingham
Birmingham, Alabama, United States - Heart Center Research, Llc
Huntsville, Alabama, United States - (and 1011 more...)
|
16 |
NCT01663402 |
Completed |
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab |
|
- Drug: alirocumab
- Drug: Placebo
|
Interventional |
Phase 3 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Time from randomization to first occurrence of one of the following clinical events: CHD death, any non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization
- Time to the first occurrence of any CHD event, major CHD event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke, all cause mortality
- Change from baseline in blood lipids and lipoprotein levels
|
18600 |
All |
40 Years and older (Adult, Senior) |
NCT01663402 |
EFC11570 2011-005698-21 U1111-1127-4323 |
|
October 2012 |
January 23, 2018 |
January 23, 2018 |
August 13, 2012 |
February 14, 2018 |
|
- Investigational Site Number 840163
Birmingham, Alabama, United States - Investigational Site Number 840060
Birmingham, Alabama, United States - Investigational Site Number 840117
Huntsville, Alabama, United States - (and 1385 more...)
|
17 |
NCT00162643 |
Unknown † |
PI Vs. NNRTI Based Therapy for HIV Advanced Disease |
- Acquired Immunodeficiency Syndrome
|
- Drug: zidovudine+lamivudine+lopinavir/ritonavir
- Drug: zidovudine + lamivudine + efavirenz
|
Interventional |
Phase 4 |
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- National Council of Science and Technology, Mexico
- Instituto Mexicano del Seguro Social
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients who reach HIV-1-RNA ≤ 50 copies/mL at 48 weeks
- plasma Viral Load change from baseline
- Clinical symptoms
- (and 4 more...)
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT00162643 |
SALUD-2003-C01-123 |
|
December 2004 |
|
December 2007 |
September 13, 2005 |
September 14, 2006 |
|
- Hospital de Especialidades Centro Medico Nacional siglo XXI
Mexico City, D.f., Mexico - Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, DF, Mexico - Hospital General Regional #53
Los Reyes La Paz, Estado de Mexico, Mexico - (and 2 more...)
|
18 |
NCT02963246 |
Recruiting |
Mindfulness Therapy in Inflammatory Bowel Disease |
|
|
Interventional |
Not Applicable |
- Cardenal Herrera University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Quality of life measured with the IBDQ-32 (Inflammatory Bowel Disease Questionnaire)
- inflammation stress markers (reactive Protein C and faecal calprotectin)
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT02963246 |
UNIVERSITY CARDENAL HERRERA-4 |
Mindfulness |
May 5, 2017 |
February 2018 |
March 2018 |
November 15, 2016 |
July 31, 2017 |
|
- Universidad CEU Cardenal Herrera
Elche, Spain
|
19 |
NCT01171404 |
Completed |
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge |
- ACS
- Acute Coronary Syndrome
- Myocardial Infarction
- (and 2 more...)
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Clinical outcomes (ischemic and bleeding) incidence and time to these clinical outcomes
- Antithrombotic treatments
- Use of health care resources
- Quality of life
|
10568 |
All |
18 Years and older (Adult, Senior) |
NCT01171404 |
NIS-CEU-DUM-2009/1 |
EPICOR |
September 2010 |
March 2013 |
March 2013 |
July 28, 2010 |
April 17, 2013 |
|
- Research Site
Avellaneda, Argentina - Research Site
Bahia Blanca, Argentina - Research Site
Ciudad Autonoma de Buenos Aires, Argentina - (and 408 more...)
|
20 |
NCT01000727 |
Completed Has Results |
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial |
|
- Drug: Darapladib 160 mg
- Drug: Placebo
- Other: Standard Therapy
|
Interventional |
Phase 3 |
- GlaxoSmithKline
- The TIMI Study Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV) Event
- Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal MI or Non-fatal Stroke) During the Time Period for Follow-up of CV Events
- Number of Participants With Cardiovascular Death During the Time Period for Follow-up of Cardiovascular Events
- (and 9 more...)
|
13026 |
All |
18 Years and older (Adult, Senior) |
NCT01000727 |
480848/033 |
SOLID-TIMI 52 |
December 1, 2009 |
April 1, 2014 |
April 24, 2014 |
October 23, 2009 |
August 10, 2017 |
August 10, 2017 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Huntsville, Alabama, United States - (and 913 more...)
|
21 |
NCT01042769 |
Completed |
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus |
|
- Drug: Aleglitazar
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke
- Effects on other cardiovascular endpoints
- Glycemic control, lipoprotein profile, blood pressure, biomarkers of cardiovascular risk
- Tolerability and long-term safety profile
|
7226 |
All |
18 Years and older (Adult, Senior) |
NCT01042769 |
BC22140 2009-012269-71 |
|
February 2010 |
November 2013 |
November 2013 |
January 6, 2010 |
November 2, 2016 |
|
- Birmingham, Alabama, United States
- Birmingham, Alabama, United States
- Mobile, Alabama, United States
- (and 809 more...)
|